Clinical Applications of Selected Reaction Monitoring-Based Mass Spectrometry Assays

Skip to Navigation


  • Date: Mar 30, 2011 - 15:00 - 16:00 (local time)
  • Categories: Proteomics & Genomics / Proteomics
thumbnail image: Clinical Applications of Selected Reaction Monitoring-Based Mass Spectrometry Assays

Free webinar
from Thermo Scientific

Thermo Scientific

Clinical Applications of Selected Reaction
Monitoring-Based Mass Spectrometry Assays

Vathany Kulasingam, Ph.D.
Clinical Biochemist & Assistant Professor, University of Toronto

  • Register now >>>
  • Already registered? Login using the link in your confirmation email.


In this interactive webinar, a multiplexed SRM-based assay to verify biomarkers for differential diagnosis of azoospermia is discussed, highlighting its ability to simultaneously quantify 30 proteins using MS.

Also presented is an assay utilizing immuno-enrichment to extract prostate-specific antigen from complex mixtures, allowing quantification in the low ng/mL range.

Finally, the results of a study assessing the transferability and reproducibility of SRM assays between clinical research laboratories are highlighted.

Who should attend?

  • Proteomics researchers who need to quantitatively verify and validate putative biomarkers
  • Clinicians seeking to develop mass spectrometry-based screening assays for protein biomarkers
  • Collaborative researchers who need to achieve consistent, reliable results when data is collected by multiple instruments in multiple facilities
  • Anyone interested in the discovery and application of protein biomarkers

More information

While numerous strategies exist for biomarker discovery, the bottleneck to routine use at the clinic is in the verification and validation phases of candidate biomarkers. In particular, a major limiting factor in getting markers to the clinic is the lack of assays and other methods for quantitative validation of discovered candidates. Using selected reaction monitoring (SRM)-based mass spectrometry (MS), multiple proteins in the low µg/mL concentration can be monitored and quantitated simultaneously in unfractionated digests of complex mixtures.

However, to quantify very low abundance proteins (low ng/mL), immuno-mass spectrometry-based methods are necessary and have been developed for some analytes. In addition, reliable quantification requires that the MS-based assays are robust, selective, and reproducible. Thus, the development of standardized protocols is also essential in order to introduce protein quantification by MS into clinical laboratories.

Your speaker...

Dr. Vathany Kulasingam Dr. Vathany Kulasingam completed her PhD at the Department of Laboratory Medicine and Pathobiology, University of Toronto, under the leadership of Dr. Eleftherios P. Diamandis. Her doctoral thesis focused on discovery and validation of novel breast cancer biomarkers by use of tissue culture model systems, in association with quantitative mass spectrometry. Following her PhD, she completed a post-doctoral training diploma program in Clinical Chemistry at the University of Toronto.

Dr. Kulasingam is currently an academic clinical biochemist at the University Health Network and an Assistant Professor at the Faculty of Medicine, University of Toronto. Her current interests include novel tumor biomarker discovery and application of proteomics to clinical practice.


Register now >>>

Thermo Scientific 

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Most Viewed

Copyright Information

Interested in spectroscopy? Visit our sister site

Copyright © 2018 John Wiley & Sons, Inc. All Rights Reserved